Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Reham Mostafa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chest Hospital, Ministry of Health, Assiut, Egypt. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Ciprofloxacin, Meropenem, Klebsiella Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Science, Technology & Innovative Funding Authority, One Health Grant.
Abstract (Originalsprache)
Background
Despite the growing concern over MDR hypervirulent Klebsiella pneumoniae (MDR-hvKP), effective treatments remain limited.
Aim
This study explores the potential of co-loading ciprofloxacin and meropenem into a nano-polymeric matrix to enhance their synergistic activity against MDR-hvKP and improve treatment outcomes in a hvKP-infected rat model.
Methods
Ten clinical K. pneumoniae isolates were tested for virulence genes (p-rmpA, iucA) to confirm the presence of hvKP. The synergistic activity of free-ciprofloxacin/meropenem and nanosized ciprofloxacin/meropenem was evaluated using checkerboard and time–kill assays. Survival rates and bacterial burden were assessed in a rat sepsis model after receiving either nano- or free-ciprofloxacin/meropenem.
Results
HvKP strains exhibited significantly lower MICs for nanosized drugs compared with free drugs. MICs of nano-ciprofloxacin ranged from 2 to 32 mg/L, and nano-meropenem from 0.125 to 64 mg/L, reflecting 2–4- and 4–16-fold reductions compared with free drugs. Nano- ciprofloxacin/meropenem combination displayed synergistic activity against 7 out of 10 hvKP strains and additive activity against three strains. By contrast, free-ciprofloxacin/meropenem showed synergy in only two strains, additive effects in two strains and indifferent activity in six strains. Time–kill assays demonstrated that monotherapies failed to inhibit bacterial growth, while nanosized combination exhibited bactericidal activity at 1×MIC. Nano-ciprofloxacin/meropenem significantly improved survival and reduced bacterial load compared with free drugs combination (P ≤ 0.0001).
Conclusion
Dual antibiotic-loaded nanoparticles represent an innovative therapeutic approach against hvKP infections and highlight nanotechnology's potential in overcoming MDR pathogens for future clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chest Hospital, Ministry of Health, Assiut, Egypt.
- Medical Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
- Assiut International Center of Nanomedicine, Al-Rajhy Liver Hospital, Assiut University, Assiut 71515, Egypt.
- Microbiology and Immunology Department, School of Biotechnology, Badr University in Assiut, Assiut, Egypt.
Förderung
- Science, Technology & Innovative Funding Authority
- One Health Grant
Zitieren
APA
Mostafa, R., Mohammed, S., Ahmed, A. S., Aly, S. A., & Hadiya, S. (2026). Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf422
Vancouver
Mostafa R, Mohammed S, Ahmed AS, Aly SA, Hadiya S. Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf422
BibTeX
@article{Mostafa2026,
author = {Mostafa, Reham and Mohammed, Shereen and Ahmed, Ahmed S and Aly, Sherine A and Hadiya, Safy},
title = {Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf422}
}
EUVIMED